SMAD2 and neoplasm: The YAP-Smad2/3 complex may cooperatively recruit different co-activators or epigenetic regulators across various cancer types, altering the transcriptional target gene profile and enabling the TGF-β pathway to switch from tumor-suppressive to tumor-promoting roles.